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The protein kinase (PK) encoded by the Epstein-Barr Virus (EBV) BGLF4 gene is the only EBV protein
kinase. The expression pattern of EBV PK during the reactivation of the viral lytic cycle and the subcellular
localization of the protein were analyzed with a polyclonal antiserum raised against a peptide corresponding
to the N terminus of EBV PK. Based on previously published data (E. Gershburg and J. S. Pagano, J. Virol.
76:998-1003, 2002) and the expression pattern described here, we conclude that EBV PK is an early protein that
requires viral-DNA replication for maximum expression. By biochemical fractionation, the protein could be
detected mainly in the nuclear fraction 4 h after viral reactivation in Akata cells. Nuclear localization could be
visualized by indirect immunofluorescence in HeLa cells transiently expressing EBV BGLF4 in the absence of
other viral products. Transient expression of 3-terminal deletion mutants of EBV BGLF4 resulted in cyto-
plasmic localization, confirming the presence of a nuclear localization site in the C-terminal region of the
protein. In contrast to the wild-type EBV PK, all of the mutants were unable to hyperphosphorylate EA-D
during coexpression or to phosphorylate ganciclovir, as measured by an in-cell activity assay. Thus, the results
demonstrate that the nuclear localization, as well as the kinase activity, of BGFL4 is dependent on an intact
C-terminal region.
Many large DNA viruses encode their own protein kinases that
manage different aspects of virus replication and virus-cell inter-
actions (21). Phosphorylation of cellular and viral proteins, which
has been observed during lytic infection of cells by herpesviruses,
seems to be a common phenomenon that involves a number of
different protein kinase activities (17). Two groups of viral protein
kinases (PKs) have been identified in herpesviruses. Alphaher-
pesviruses encode members of both groups. The US3 gene of
herpes simplex virus type 1 (HSV-1) (28) exemplifies the first
group, which was first predicted to encode protein kinases on the
basis of strong similarity to the family of eukaryotic serine/thre-
onine protein kinases. Later, a number of targets for this kinase,
such as HSV UL34 (35), US9 (14), UL12 (15), and the cellular
proapoptotic protein BAD (15), were identified. UL13, the rep-
resentative of a second group, has been shown to phosphorylate
the viral proteins ICP22 (34), gE and gI (30), and ICP0 (31), as
well as cellular translation elongation factor 1 delta (20) and p60
(6). Despite the facts that US3 is involved in the inhibition of
apoptosis (2, 22) and both US3 and UL13 regulate a number of
key factors, both seem to be dispensable for the replication of
HSV-1 in vitro (12, 16, 24).
Beta- and gammaherpesviruses encode only protein kinases
belonging to the second group, with homology to HSV UL13.
This group, identified by sequence homology, includes UL97 of
human cytomegalovirus (HCMV), BGLF4 of Epstein-Barr virus
(EBV) (36), U69 of human herpesvirus 6 (1), ORF36 of Kaposi’s
sarcoma-associated herpesvirus (33), and a few others. This sub-
group of UL protein kinases is evolutionarily more distant from
the cellular protein kinases than are the alphaherpesvirus US
protein kinases. Some members of this group, such as UL97, U69,
BGLF4, and ORF36, have been shown to phosphorylate ganci-
clovir (GCV) (1, 7, 23, 26, 37). The functions of herpesvirus PKs
are not fully understood; however, the relatively high degree of
conservation of these kinases can be attributed to their impor-
tance for the replication of these viruses in their natural hosts and
their possible role in viral pathogenesis.
EBV BGLF4 was first identified as a Ser/Thr protein kinase-
related gene by the use of amino acid sequence alignment of
regions conserved within the catalytic domains of protein kinases
(36), and the BGLF4 protein is the only potential protein kinase
identified in the EBV genome. Recently, several groups have
reported protein kinase activity associated with BGLF4-encoded
protein (9, 18, 19); however, the characterization of the protein
remains incomplete. In this report, we fill several gaps in knowl-
edge about EBV PK: (i) it is detected in immunoblotting as a
single band at 49 kDa (the predicted molecular mass is 51 kDa);
(ii) it is expressed as early as 4 h after viral reactivation in Akata
cells, and protein expression peaks between 12 and 24 h; (iii) the
protein is localized in the nuclei of induced Akata or transfected
HeLa cells; (iv) while computer analysis did not detect any known
nuclear localization sites (NLS, 3-terminal deletion mutants of
BGLF4 exhibited cytoplasmic localization, suggesting the exis-
tence of a noncanonical NLS in the C terminus of the protein; (v)
all mutants failed to hyperphosphorylate EA-D and to phosphor-
ylate GCV.
MATERIALS AND METHODS
Cell culture. Akata is a Burkitt’s lymphoma (BL) cell line latently infected with
EBV (38), DG75 is an EBV-negative BL cell line (4), HeLa is a cervical ade-
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nocarcinoma cell line (ATCC CCL2), and HEK293 is a permanent line of
primary human embryonal kidney cells transformed by sheared human adeno-
virus type 5 DNA (ATCC CRL1573). The cells were grown as described previ-
ously (40).
Treatment of cells with antiviral compounds and viral reactivation. Maribavir
(previously designated 1263W94) was supplied by GlaxoSmithKline. Exponen-
tially growing cells were centrifuged at 800  g and suspended in fresh medium
containing different concentrations of the compound for an appropriate time. At
the end of the treatment, cells were harvested and analyzed depending on the
aim of the experiment.
To reactivate viral lytic infection, Akata cells were treated with goat anti-
human immunoglobulin G (0.1 mg/ml; Sigma). Treatment with the antiviral
compound and viral reactivation were begun at the same time.
Plasmids and transfections. Cloning of the EBV BGLF4 open reading frame
(ORF) has been described previously (18). 3-truncated mutants were con-
structed by PCR amplification using the cloned EBV BGLF4 ORF as a template,
the PK-5 oligonucleotide (5-CCGGATCCCAGCGGGTGGAGG-3) as a 5
primer for all mutants, and PK-3 (5-GAATTCCTATCCACGTCGGCCATC-
3), PK-(1-374)-3 (5-GAATTCCTACGTGACATCCACGCAC-3), PK-(1-
169)-3 (5-GAATTCCTACTCAATACTACCATC-3), or PK-(1-74)-3 (5-GA
ATTCCTAATCACAGCGCGTCATG-3) as a 3 primer for full-length PK and
mutants expressing the first 374, 169, or 74 amino acids (aa), respectively. The
amplified fragments were cloned into pFLAG-CMV2 (Sigma); the resulting
plasmids were designated pFPK-FL, pFPK-(1-374), pFPK-(1-169), and pFPK-
(1-74). The full-length BGLF4 ORF was also cloned into the vector pEGFP-C1
(Clontech); the resulting plasmid was designated pEGFP/PK. The plasmids
pcDNA-UL97, pcDNA-UL97(K355 M), and pcDNA-BGLF4-Flag were de-
scribed previously (26). HeLa or 293 HEK cells were transfected with the use of
Effectine (QIAgen) following the manufacturer’s protocol. Transfected cells
were cultured in Dulbecco’s modified Eagle’s medium supplemented by 10%
fetal bovine serum and antibiotics for 24 to 48 h at 37°C and then harvested for
analysis.
Antibodies, immunoblotting, and indirect immunofluorescence (IF). Mono-
clonal antibodies against -tubulin and FLAG (M2) were purchased from Sigma
and used at 1:5,000 and 1:3,000 dilutions, respectively. Anti-GRP-78 was pur-
chased from Santa Cruz Biotechnology and used at 1:500 dilution. Purified
anti-PK antibody was used at a dilution of 1:250. Secondary donkey anti-mouse
and anti-rabbit horseradish peroxidase-conjugated antibodies were purchased
from Amersham (1:5,000).
The preparation of whole-cell lysates and immunoblotting were described
FIG. 1. EBV PK expression during viral reactivation in Akata cells. (A) Equal amounts of whole-cell lysates from the HeLa cells transfected
with pEGFP/PK or pHD/PK, Akata cells (24 h after viral reactivation), and DG-75 cells were subjected to SDS-PAGE, followed by immunoblotting
with the affinity-purified anti-PK antibody. (B) Akata cells were collected at different time points after viral lytic reactivation in the presence or
absence of maribavir, and equal amounts of the whole-cell lysates were analyzed by immunoblotting them with anti-PK antibody. Lanes 1 to 6, no
maribavir; lanes 7 to 12, samples treated with 10 M maribavir. Lanes 1 and 7 are latent Akata cells. Nonspecific bands detected by the antibody
are marked N/S.
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previously (18). For IF, cells were fixed with 3.7% formaldehyde for 10 min,
followed by additional fixation and permeabilization in cold acetone for 5 min.
EBV EA-D was detected by incubation with R3 monoclonal antibody (a gift
from J. Luka) at 1:500 dilution, followed by donkey anti-mouse Alexa-594-
conjugated antibody (Molecular Probes) (1:100). EBV PK staining was per-
formed by incubation with a 1:100 dilution of the purified anti-PK antibody,
followed by donkey anti-rabbit Alexa-488-conjugated antibody at a 1:100 dilu-
tion. Nuclei were stained with Hoechst stain (1:100). Samples were analyzed with
a Zeiss Axiophot microscope using a 63 or 100 objective, and digital images
were captured with Metamorph imaging software (Universal Imaging Corp.) and
a MicroMAX 5-MHz cooled charge-coupled device camera (Princeton Instru-
ments).
In-cell activity assay. The in-cell activity assay was described in detail previ-
ously (27). Briefly, 293 HEK cells were transfected with appropriate plasmid
DNA according to the Lipofectamine procedure (Lipofectamine Plus reagents;
Gibco BRL). Twenty-four hours posttransfection the media were replaced by
diluted GCV (concentrations, 0 to 160 M). On day 7, color changes were
quantified by measuring an optical density at 560 nm.
RESULTS
Temporal expression of EBV PK after viral lytic reactivation
in Akata cells. To study the expression pattern of the BGLF4
gene product, we first produced antibody against EBV PK.
New Zealand White rabbits were immunized with a peptide
corresponding to the N terminus of the EBV PK protein fol-
lowing standard protocols. To achieve the desired specificity,
the resulting antiserum was subsequently purified by affinity
chromatography on EBV PK-bound resin. Figure 1A illus-
FIG. 2. Subcellular localization of EBV PK. (A) Akata cells were collected at the indicated time points after viral reactivation, and nuclear and
cytoplasmic fractions were subjected to SDS-PAGE and analyzed by immunoblotting. Lanes 5 to 10 and 15 to 18, samples treated with 10 M
maribavir. GRP-78 served as a cytoplasmic marker. (B) Indirect immunofluorescence of the HeLa cells transfected with pHD/PK alone or
cotransfected with pHD/PK and pHD/EA-D. i, preimmune serum; ii, anti-PK serum; iii, anti-PK and anti-EA-D serum. In i and ii, red is actin and
green is PK; in iii, red is EA-D, green is PK, and blue is nuclei.
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trates the specificity of the purified antiserum toward EBV PK.
The EBV PK antibody detected a specific band at 49 kDa in
induced Akata cells (Fig. 1A, lane 3) and in HeLa cells tran-
siently expressing EBV PK (Fig. 1A, lanes 1 and 2) but not in
EBV-negative DG-75 cells (Fig. 1A, lane 4). The molecular
mass of the protein detected by immunoblotting is in agree-
ment with the predicted molecular mass of 51 kDa, which has
been calculated based on the amino acid sequence. A nonspe-
cific band at 70 kDa was detected in all tested samples,
perhaps due to cross-reactivity with a cellular protein. No spe-
cific signal was detected with preimmune serum in both in-
duced Akata and BGLF4-expressing HeLa cells (data not
shown).
Previously, it was shown that the antiviral compound
maribavir affected the kinetics of appearance of pp58, the
hyperphosphorylated form of EA-D, in Akata cells during viral
reactivation (18). In this study, we used the same treatment in
order to assess the effect of maribavir on EBV PK kinetics. The
EBV cytolytic cycle was induced by immunoglobulin G treat-
ment (see Materials and Methods) in the presence or absence
of 10 M maribavir, and the expression pattern of the EBV PK
protein was analyzed by immunoblotting (Fig. 1B). The anal-
ysis revealed that EBV PK appears as early as 4 h postinduc-
tion (p.i.) (Fig. 1B, lane 2), peaks between 12 and 24 h p.i. (Fig.
1B, lanes 4 and 5), and is slightly reduced at 48 h p.i. (Fig. 1B,
lane 6). The protein levels were significantly reduced after
treatment with maribavir (Fig. 1B, compare lanes 2 to 6 to
lanes 8 to 12). Previous data (18) indicated that the inhibition
of EBV DNA synthesis by maribavir temporally coincided with
inhibition by acyclovir, a known inhibitor of EBV replication.
Therefore, these results confirm at the protein level that the
BGLF4 gene is an early or early-late gene that expresses rel-
atively low levels of protein under early conditions (maribavir
treatment), with maximum expression coinciding with viral-
DNA replication.
EBV PK intracellular localization during viral reactivation
in Akata cells and during transient expression in HeLa cells.
HCMV UL97, an EBV PK homolog, has been detected in the
nuclei of infected cells (29). Also, it was recently shown that
EBV PK is associated with phosphorylation of the EBV
BMRF1 product, EA-D, in vivo (18), and Chen et al. (9) have
phosphorylated EA-D with EBV PK in vitro. EA-D is a known
nuclear protein (11). However, the intracellular localization of
EBV PK protein has not been clearly demonstrated. To ad-
dress this question, we employed IF analysis and protein ex-
tract fractionation, followed by immunoblotting. Akata cells
were treated as described above and subjected to biochemical
partition by the use of a commercial kit (Pierce) following the
manufacturer’s protocol. The extracts were separated on so-
dium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) and analyzed by immunoblotting. The results show
that most of the PK is detected in the nuclear fraction (Fig. 2A,
lanes 11 to 17), while some of the protein could be detected in
the cytoplasm (Fig. 2A, lanes 1 to 4). Treatment with maribavir
strongly reduced the EBV PK levels in both the nucleus and
the cytoplasm (Fig. 2A, lanes 6 to 9 and 15 to 18).
To determine whether the nuclear localization of EBV PK is
dependent on other EBV proteins, we performed indirect im-
munofluorescence analysis of HeLa cells transiently expressing
the BGLF4 gene. EBV PK was detected only in the nuclei of
transfected cells 24 h posttransfection (Fig. 2B, ii). Moreover,
the EBV PK colocalized with EBV EA-D when both were
coexpressed in HeLa cells (Fig. 2B, iii). These findings indicate
that no other EBV proteins are required for nuclear localiza-
tion of the EBV PK protein.
Putative NLS of EBV PK protein. To analyze further the
nuclear translocation of the EBV PK protein, a number of
C-terminally truncated mutants were created (Fig. 3A). The
mutants were transiently expressed in 293 HEK or HeLa cells,
and their expression was analyzed by protein extract fraction-
ation. The analysis showed that all of the mutants were local-
ized in the cytoplasm with only trace amounts detected in the
nuclei (Fig. 3B). These results suggest the existence of an NLS
in the C-terminal region of the protein between aa 374 and
429. Sequence analysis of this region revealed a cluster of basic
amino acids that could serve as a putative NLS (RSLKKRFK);
however, no significant homology with any of the known NLS
was found.
Kinase activity of EBV PK mutants. In order to further
characterize the activities of the EBV PK mutants, we used two
previously established assays. First, we tested the abilities of
the mutants to hyperphosphorylate EBV EA-D during coex-
pression in 293 HEK cells, and second, we tested their abilities
to phosphorylate GCV. The results presented in Fig. 4A dem-
onstrate that all of the mutants failed to hyperphosphorylate
EA-D (the detected band corresponds to the pp50 hypophos-
phorylated form and migrates similarly to EA-D expressed
FIG. 3. Expression of EBV PK mutants. (A) Summary of BGLF4
mutants. I to IV are the putative functional domains, based on align-
ment of different kinases. The basic amino acid cluster, catalytic lysine,
and FLAG tag are shown as well. The different mutants were gener-
ated by PCR, as described in Materials and Methods. (B) The mutants
were transfected into HEK 293 cells; 48 h after transfection, the cells
were fractionated, and the nuclear and the cytoplasmic fractions were
subjected to SDS-PAGE and analyzed by immunoblotting them with
anti-FLAG antibody.
VOL. 78, 2004 EXPRESSION AND LOCALIZATION OF EBV-ENCODED PK 12143
alone), while wild-type PK cloned in the same manner func-
tioned properly (the band detected corresponds to the pp58
hyperphosphorylated form). The in-cell activity assay also
showed a lack of GCV phosphorylation by all the EBV PK
mutants in comparison to the wild-type EBV PK (Fig. 4B).
Thus, the results showed the importance of the intact C ter-
minus of the EBV PK protein for its proper functioning.
DISCUSSION
Herpesvirus-encoded protein kinases have attracted increas-
ing attention lately due to the growing evidence of their in-
volvement in different aspects of viral life cycles, which makes
them appealing targets for antiviral compounds. The HSV-1
UL13 and HCMV UL97 PKs have been studied extensively,
whereas the EBV PK has remained largely uncharacterized. In
this study, we have addressed a number of questions, including
the expression pattern of the protein during viral lytic reacti-
vation and its intracellular localization in different cell lines. To
answer these questions, we have used a polyclonal antiserum
raised against a peptide corresponding to the N terminus of the
protein. The antiserum was affinity purified on a PK-bound
column (Fig. 1A). This antiserum made possible direct detec-
tion of the protein, in contrast to previous studies in which
epitope-tagged proteins and tag-directed antibodies were used
(9, 10).
Previously, we reported that EBV BGLF4 is an early gene
based on its mRNA levels throughout viral reactivation in
Akata cells in the presence of maribavir or acyclovir. The
results demonstrated early kinetics comparable to the pattern
of expression of the EBV BMRF1 protein, EA-D (18). The
results of the present study of the EBV PK protein expression
pattern are in agreement with the RNA data (Fig. 1B); inter-
estingly, The PK protein could be detected earlier then EA-D,
which correlates with its involvement in EA-D posttransla-
tional modification (18). In contrast to the RNA level, which
waned 48 h after viral reactivation, the protein level was sub-
stantial at this time (18) (Fig. 1B), which may imply that the
protein is relatively stable. Another interesting observation
made in the course of this study is that although maribavir was
reported to be an enzymatic inhibitor (3, 5), we consistently
observed overall reduction in the levels of different viral pro-
teins (Fig. 1B) (18; E. Gershburg and J. S. Pagano, unpub-
FIG. 4. Kinase activities of EBV PK mutants. (A) Hyperphosphorylation of EBV EA-D. The mutants were transfected, along with pHD/
BMRF1, into HEK 293 cells; 48 h after transfection, the cells were collected, and the whole-cell lysates were subjected to SDS-PAGE and analyzed
by immunoblotting them with EA-D antibody. (B) In-cell activity assay. The cells were treated as described in reference 27 and Materials and
Methods. All measurements were based on triplicate transfections in three independent experiments. Mean and standard deviation values are
shown. OD560, optical density at 560 nm.
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lished data), as well as changes in the mRNA profile of at least
one EBV gene (Gershburg and Pagano, unpublished). Thus,
we cannot exclude the possible effect of the compound on
transcription and translation, and we are investigating these
possibilities.
Our results reveal that the protein encoded by the EBV
BGLF4 gene has the intrinsic capacity for nucleus transloca-
tion even in the absence of other EBV proteins. This was
clearly shown in HeLa cells, in which the protein was tran-
siently expressed (Fig. 2); furthermore, coexpression of EBV
PK with EA-D resulted in their colocalization, as detected by
indirect immunofluorescence (Fig. 2). These data are in agree-
ment with previously published results that demonstrated nu-
clear localization of HSV UL13 (13), HCMV UL97 (29), and
Kaposi’s sarcoma-associated herpesvirus ORF36 (33). How-
ever, they contradict the data published by Chen et al., who
reported cytoplasmic localization of EBV BGLF4 (9). The
abnormal localization of the BGLF4 product in transient ex-
pression could be caused by the EBNA-1 tag system used in
that study (10). In contrast, our results are consistent in dif-
ferent cell types and with the use of different methods (immu-
nofluorescence or cell partitioning followed by immunoblot-
ting); in addition, the FLAG-tagged version of the protein was
expressed similarly to the wild-type protein (Fig. 1 and 3B).
Nuclear uptake of proteins is a highly selective signal-medi-
ated process. The proteins that are actively translocated into
the nucleus have been shown to possess a specific NLS (re-
viewed in reference 25). A single cluster of basic amino acids
(RSLKKRFK) is located in the C terminus of EBV PK, and
deletion of the last 55 aa resulted in cytoplasmic retention of
the protein (Fig. 3). In contrast to the observation with HCMV
UL97, where deletion of the putative NLS resulted in mixed
distribution of the protein that was attributed to a second basic
region (29), EBV BGLF4 possesses only one basic region,
deletion of which resulted in the cytoplasmic localization of all
tested mutants. These data suggest that the protein possesses
only one putative NLS, which is located in the C terminus;
however, we were unable to find significant homology between
the basic cluster found in EBV PK and any known NLS.
Known viral NLS are the classical monopartite [B4, P(B3X),
PXX(B3X), and B3(H/P)], bipartite [BBX10(B3X2)], or argi-
nine-rich (RXXRRX1,2RBR) regions, in which B is a basic
residue (K or R) and X is any residue (25, 32, 39), whereas,
although it remotely resembles a viral NLS motif, the EBV PK
cluster (RXXKKRXK) is not a perfect match. Therefore, we
are attempting to elucidate the importance of each one of the
residues in this motif for protein nuclear translocation.
In assessing the functional properties of the mutants, we
examined their abilities to hyperphosphorylate EBV EA-D
and to phosphorylate GCV. None of the mutants were active in
these two assays, including pFPK-(1-374), which lacks only 55
aa. Since this mutation did not affect any regions important for
the kinase activity (8, 9), it is possible that the lack of activity
resulted from the subcellular localization of the kinase mu-
tants. This hypothesis is being tested in our laboratory.
The new data presented in this report improve our under-
standing of the biology and functions of EBV-PK. Studies to
better understand EBV PK nuclear translocation, as well as to
identify new viral and cellular targets of the kinase, are under
way.
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